Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2024)
35 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 8, 2024
Slide 1: AGM Chairman's Address and Investor Presentation
ASX Release 8 November 2024 ASX code: PIQ AGM Chairman’s Address and Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of the Chairman’s Address to be provided by Mr Neville Gardiner and the Investor Presentation to be p
Slide 2: Chairman's Address
Chairman’s Address Good Morning Ladies and Gentlemen My name is Neville Gardiner, and as Chair of the company it is my pleasure to welcome you to the 10th Annual General Meeting of shareholders of Proteomics International Laboratories. It is now after 9:30 am, and as we have a quorum of shareholders
Slide 3: Proteomics International AGM Presentation
ASX: PIQ Proteomics International LABORATORIES LTD AGM Presentation 8 November 2024 Dr. Richard Lipscombe Managing Director 1
Slide 4: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 5: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ A medical technology company at the forefront of predictive diagnostics and precision medicine Commercialising three first-in-class tests driven by a proprietary platform technology: • A novel and accurate test for predicting the onset of chronic ki
Slide 6: Corporate Overview
Corporate Overview ASX: PIQ Financial and Corporate Corporate Snapshot ASX code PIQ • Top 40 Shareholders hold 41% Market Capitalisation A$91m Cash (30 Sept 2024) (+ R&D Tax Incentive ~$2m H1 FY25) ~A$5.1m • Directors are highly aligned with shareholders holding 14% Share Price (6 Nov 2024) A$0.70 •
Slide 7: Science Proven – Commercialisation Underway
Science Proven – Commercialisation Underway ASX: PIQ Over 20 years R&D experience Each test has whole of market resulting in deep pipeline appeal • 3 highly accurate tests commercialisation ready • Pharma • Large unmet medical needs • Clinical pathology labs • Will save patient lives & improve quali
Slide 8: The Problem: target populations for DKD, Endo & Eso
The Problem: target populations for DKD, Endo & Eso ASX: PIQ 10.5% of global adult population 1 in 9 women have 1-2% of western populations at risk have diabetes endometriosis of Esophageal Cancer (Diagnosed by endoscopy with biopsy) 537m adults 378m 20-120m adults globally with women in eligible fo
Slide 9: The Solution: precision medicine targeting unmet needs
The Solution: precision medicine targeting unmet needs ASX: PIQ Diabetic Kidney Disease Endometriosis Esophageal Cancer • 1-in-3 with diabetes currently • Potential target is all pre- • 1 in 20 cancer deaths have chronic kidney disease menopausal women globally worldwide due to esophageal • Promarke
Slide 10: Go-to-Market Pathways
Go-to-Market Pathways ASX: PIQ Proteomics International is pursuing a hybrid G2M strategy for its suite of novel diagnostic tests Traditional licensing model Promarker Hub Diagnostic laboratory Laboratory runs test via Laboratory pays PI a licences the test automated processes royalty per test Reage
Slide 11: Launch Strategy for DTP
Launch Strategy for DTP ASX: PIQ Establishing first sales via DTP builds product awareness and drives mainstream use and subsequent volume Step 1 Step 2 Step 3 Step 4 Engage patients Motivate patients Provide patient Drive and Grow sales Swiftly position access • Direct to consumer • Understand thei
Slide 12: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 10
Slide 13: Pipeline of Precision Diagnostics
Pipeline of Precision Diagnostics ASX: PIQ Platform technology drives deep pipeline of novel diagnostic tests Further global potential in new markets • Promarker platform develops novel intellectual property • Targeting new diagnostic tests in areas of significant unmet need • Enormous markets and r
Slide 14: PromarkerD Global Rollout – Key Highlights
PromarkerD Global Rollout – Key Highlights ASX: PIQ Intellectual Property Patents granted in all major jurisdictions - PromarkerD Patent family & Trademark covers 72% of the world’s diabetes patients CE Mark (EU) registration received for the PromarkerD Immunoassay IVD Regulatory US sales utilising
Slide 15: PromarkerD: Existing partnerships
PromarkerD: Existing partnerships ASX: PIQ Proteomics International is focused on supporting its partners to achieve first sales in each jurisdiction • PromarkerD is CE Mark registered in Europe Current Steps • Detailed market assessments completed • Establish independent Reference Laboratory Europe
Slide 16: PromarkerD in the US: derisked & commercial ready
PromarkerD in the US: derisked & commercial ready ASX: PIQ Critical milestones have been achieved ✓ Centres for Medicare & ✓ Unique Proprietary ✓ Laboratory Analysis (PLA) Medicaid Services (CMS) Targeting the 32 million code established pricing established people with diabetes in the allows future
Slide 17: PromarkerEndo: Endometriosis
PromarkerEndo: Endometriosis ASX: PIQ World-first blood test ‘PromarkerEndo’ nearing commercialisation Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) symptomatic patients (pelvic pain but surgically-diagnosed absence of endometriosis) 3) endometriosis pat
Slide 18: PromarkerEso: Esophageal Cancer
PromarkerEso: Esophageal Cancer ASX: PIQ World-first blood test ‘PromarkerEso’ ready for commercialisation Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) esophageal adenocarcinoma (EAC) patients ➢ Only 50% of EAC patients report chronic acid reflux ➢ 90%
Slide 19: Dx Pipeline: Oxidative Stress
Dx Pipeline: Oxidative Stress ASX: PIQ Potential world-first blood test in late-stage development What is Oxidative Stress? Targeting commercial use of OxiDx technology: • Oxidative stress occurs when the body’s ➢ Athletic monitoring tool for competition preparedness: antioxidant defences are overwh
Slide 20: Timeline & Milestones
Timeline & Milestones ASX: PIQ FY24-25 Achievements 1 Jan 2024 25 Mar 2024 PromarkerD CMS (USA) PromarkerEndo - 23 Aug, 11 Oct 2024 reimbursement pricing agreement with PromarkerD predicts effective Oxford University for CKD in type 1 diabetes international study 17 Jun 2024 23 Sept 2024 20 Dec 2023
Slide 21: Multiple Value Drivers in FY25
Multiple Value Drivers in FY25 ASX: PIQ Potential Share Price Catalysts throughout FY25 Milestone TARGET Qtr Dec Mar Jun Impact Exceptional Global Opportunity Commercial ➢ Disruptive, cutting-edge technology & First Sales PromarkerD in USA Initiate pathway to significant revenues proven in-house dia
Slide 22: Contact
Contact ASX: PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au ASX:PIQ 20
Slide 23: Farewell Dr John Dunlop
ASX: PIQ Farewell Dr John Dunlop 10th July 1942 - 15th December 2023 Inaugural Chair, Proteomics International Director, Proteomics International, 2001 – 2018 On 15 December last year, Proteomics International and the Western Australian biotechnology industry lost one of its quiet achievers, Dr John
Slide 24: Supplemental
Supplemental 22
Slide 25: Board of Directors
Board of Directors ASX: PIQ Dr James Williams PhD (Melbourne), MBA (UWA), BSc, Hons (Aberdeen), GAICD, Non-Executive Director & Chair elect Accomplished manager, director, scientist and investor with experience covering all aspects of life-science technology translation. Involved from startup to com
Slide 26: Promarker D
Promarker D PROACTIVELY CHANGING RENAL HEALTHCARE A simple blood test for predicting diabetic kidney disease
Slide 27: PromarkerD: World Class Advisory Board
PromarkerD: World Class Advisory Board ASX: PIQ Proteomics International is supported by an international, highly acclaimed advisory board Professor Tim Davis MedSc, MB, W.Aust., DPhil Oxf., Professor Merlin Thomas MBChB, PhD, FRACP, FRACP, MRCP (UK) – Australia FAAHMS – Australia Consultant physici
Slide 28: Problem and Solution – Diabetic Kidney Disease
Problem and Solution – Diabetic Kidney Disease ASX: PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the onset Roadblock of diabetic kidney disease The P
Slide 29: PromarkerD - Patented in all Major Markets
PromarkerD - Patented in all Major Markets ASX: PIQ Diabetic Kidney Disease is becoming one of the largest burdens on healthcare systems globally Patent family & Trademark covers 72% of world’s diabetics1 45% Country Patent/Application No Patent Status No. Diabetics1 undiagnosed Australia 2011305050
Slide 30: PromarkerD – Simple Integration & Use
PromarkerD – Simple Integration & Use ASX: PIQ Blood sample drawn Biomarkers analysed Results generated by Results and intervention plan PromarkerD Hub software delivered Sample is drawn at clinic or Laboratory uses a standard Cloud based algorithm, the Clinician delivers results to patient patholog
Slide 31: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention ASX: PIQ How PromarkerD results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Ann
Slide 32: PromarkerD: Clinical Utility & Decision Impact
PromarkerD: Clinical Utility & Decision Impact ASX: PIQ Launch strategy supported by engagement with KOLs and primary care physicians Published Research1 indicates physicians would use PromarkerD to inform patient treatment decisions • 96% of physicians were likely to use PromarkerD test scores for
Slide 33: PromarkerD: Precision in the Clinic
PromarkerD: Precision in the Clinic ASX: PIQ Peer Reviewed Physician Support Outperforms Standard of Care PromarkerD tested on over 5,000 Survey of 400 Endocrinologists & • 857 community based patients tested for patients in 4-year clinical studies Primary Care Physicians (US based) existing DKD at
Slide 34: PromarkerD: Precision Medicine
PromarkerD: Precision Medicine ASX: PIQ The Need The Treatments The Utility There is a significant and growing need for Patients identified as high-risk of DKD by Complementary diagnostic intervention for diabetic kidney disease (DKD) PromarkerD now have multiple preventative Early diagnosis of DKD
Slide 35: PromarkerD: Key Publications
PromarkerD: Key Publications ASX: PIQ Prognostic Validation for Type 1 Davis TME, et al. Application of a validated prognostic protein biomarker test for renal decline in type 2 diabetes to type Diabetes 1 diabetes: The Fremantle Diabetes Study Phase II. ADC 2024. PromarkerD Demonstrates Benefit of
Proteomics International Laboratories — Shareholder Meeting (November 2024) on 6ix